BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 28238078)

  • 1. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
    Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
    Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
    Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
    J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
    Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
    Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
    BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
    Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
    Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
    Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
    Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
    Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
    Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
    Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
    Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
    Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.